Search details
1.
COVID-19 Vaccination Responses with Different Vaccine Platforms in Patients with Inborn Errors of Immunity.
J Clin Immunol
; 43(2): 271-285, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36251205
2.
Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.
Cancer Immunol Immunother
; 71(4): 979-987, 2022 Apr.
Article
in English
| MEDLINE | ID: mdl-34467417
3.
Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia.
Cancer Immunol Immunother
; 69(5): 813-824, 2020 May.
Article
in English
| MEDLINE | ID: mdl-32055920
4.
Chronic lymphocytic leukemia cells increase neutrophils survival and promote their differentiation into CD16high CD62Ldim immunosuppressive subset.
Int J Cancer
; 144(5): 1128-1134, 2019 03 01.
Article
in English
| MEDLINE | ID: mdl-30178523
5.
Neutrophils from chronic lymphocytic leukemia patients exhibit an increased capacity to release extracellular traps (NETs).
Cancer Immunol Immunother
; 66(1): 77-89, 2017 01.
Article
in English
| MEDLINE | ID: mdl-27796477
6.
The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.
Cancer Immunol Immunother
; 66(4): 461-473, 2017 Apr.
Article
in English
| MEDLINE | ID: mdl-28011996
7.
Somatic Hypermutation Defects in Common Variable Immune Deficiency.
Curr Allergy Asthma Rep
; 17(11): 76, 2017 Oct 05.
Article
in English
| MEDLINE | ID: mdl-28983794
8.
The expression of sphingosine-1 phosphate receptor-1 in chronic lymphocytic leukemia cells is impaired by tumor microenvironmental signals and enhanced by piceatannol and R406.
J Immunol
; 193(6): 3165-74, 2014 Sep 15.
Article
in English
| MEDLINE | ID: mdl-25127862
9.
Expression and function of cathelicidin hCAP18/LL-37 in chronic lymphocytic leukemia.
Haematologica
; 105(9): e465-469, 2020 09 01.
Article
in English
| MEDLINE | ID: mdl-33054065
10.
Second generation BTK inhibitors impair the anti-fungal response of macrophages and neutrophils.
Am J Hematol
; 95(7): E174-E178, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32267009
11.
CXCL12 is a costimulator for CD4+ T cell activation and proliferation in chronic lymphocytic leukemia patients.
Cancer Immunol Immunother
; 62(1): 113-24, 2013 Jan.
Article
in English
| MEDLINE | ID: mdl-22842611
12.
Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies.
Haematologica
; 103(10): e458-e461, 2018 10.
Article
in English
| MEDLINE | ID: mdl-29748439
13.
Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia.
Front Oncol
; 13: 1143881, 2023.
Article
in English
| MEDLINE | ID: mdl-37020867
14.
The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells.
Invest New Drugs
; 30(5): 1830-40, 2012 Oct.
Article
in English
| MEDLINE | ID: mdl-21887502
15.
Sphingosine kinase 1 participates in the activation, proliferation and survival of chronic lymphocytic leukemia cells.
Haematologica
; 102(7): e257-e260, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28360148
16.
CCR4 expression in a case of cutaneous Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL) and in CLL patients with no skin manifestations.
Eur J Haematol
; 87(1): 80-6, 2011 Jul.
Article
in English
| MEDLINE | ID: mdl-21443542
17.
Immunomodulatory effects of different intravenous immunoglobulin preparations in chronic lymphocytic leukemia.
Sci Rep
; 11(1): 12926, 2021 06 21.
Article
in English
| MEDLINE | ID: mdl-34155276
18.
In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia.
Front Oncol
; 11: 598319, 2021.
Article
in English
| MEDLINE | ID: mdl-34381700
19.
CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.
Haematologica
; 95(5): 768-75, 2010 May.
Article
in English
| MEDLINE | ID: mdl-20145264
20.
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages.
Haematologica
; 100(4): e140-2, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25616578